Cover Image
Market Research Report

Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Published by Koncept Analytics Product code 937373
Published Content info 121 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)
Published: May 20, 2020 Content info: 121 Pages
Description

The global antiviral drugs market is expected to reach US$70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024. The factors such as, increasing prevalence of HIV infections, upswing in international tourism, growth in geriatric population, increasing pharmaceutical R&D spending, rapid urbanization, upsurge in healthcare spending and growing awareness about various viral diseases are expected to drive the growth of the market. However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations. A few notable trends may include accelerating growth rate of infectious diseases, increasing focus on telehealth, growth in pharmaceutical Merger & acquisitions and emergence of new infectious diseases.

The global antiviral drugs market is fragmented into branded drugs and generic drugs. Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers. However, generic drugs are also gaining widespread popularity among customers due to the low cost factor, which is likely to raise its share in global market in coming years.

The fastest growing regional market was North America owing to the presence of key players in the region, availability of sophisticated healthcare infrastructure and increasing awareness of viral diseases among people. Whereas, Europe and Asia Pacific also contributed to significant shares in the global market due to the factors such as increase in patient pool of various infectious diseases and rise in the acceptance of generic drugs. However, the sudden outbreak of COVID-19 has caused a major disruption all across the world, which is leading to the massive demand for antiviral drugs for the management of infected coronavirus patients, providing the growth opportunity to the market globally.

Scope of the report:

The report provides a comprehensive analysis of the global antiviral drugs market.

The major regional markets (North America, Europe, Asia-Pacific Middle East & Africa) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Merck & Co., AbbVie Inc., Bristol-Myer Squibb, Gilead Sciences and Cipla) are also presented in detail.

Key Target Audience:

Antiviral Drugs Manufacturers

Pharmaceuticals and Biopharmaceutical Firms

End Users (Hospitals, Clinics, Pharmacies, Drugs Stores, etc.)

Investment Banks

Healthcare and Medical Consultants

Government Bodies & Regulating Authorities

Table of Contents

Table of Contents

1. Overview

  • 1.1 Introduction
  • 1.2 Viral Life Cycle
  • 1.3 Antiviral Agents
  • 1.4 Development of Antiviral Drugs
  • 1.5 Some Major Antiviral Compounds

2. Impact of COVID-19

  • 2.1 Rise in COVID-19 Death Toll
  • 2.2 Growth in Government Spending on Healthcare
  • 2.3 COVID-19 Antiviral Candidate Drugs in Trial
  • 2.4 Regional Impact

3. Remdesivir and COVID-19

  • 3.1 Remdesivir
  • 3.2 Major Clinical Studies of Remdesivir
  • 3.3 Emergency Use of Remdesivir

4. Global Market Analysis

  • 4.1 Global Antiviral Drugs Market by Value
  • 4.2 Global Antiviral Drugs Market Forecast by Value
  • 4.3 Global Antiviral Drugs Market Value by Type
    • 4.3.1 Global Branded Antiviral Drugs Market by Value
    • 4.3.2 Global Branded Antiviral Drugs Market Forecast by Value
    • 4.3.3 Global Generic Antiviral Drugs Market by Value
    • 4.3.4 Global Generic Antiviral Drugs Market Forecast by Value
  • 4.4 Global Antiviral Drugs Market Value by Application
    • 4.4.1 Global Hepatitis Antiviral Drugs Market by Value
    • 4.4.2 Global Hepatitis Antiviral Drugs Market Forecast by Value
    • 4.4.3 Global HIV Antiviral Drugs Market by Value
    • 4.4.4 Global HIV Antiviral Drugs Market Forecast by Value
    • 4.4.5 Global Influenza Antiviral Drugs Market by Value
    • 4.4.6 Global Influenza Antiviral Drugs Market Forecast by Value
    • 4.4.7 Global Herpes Antiviral Drugs Market by Value
    • 4.4.8 Global Herpes Antiviral Drugs Market Forecast by Value
  • 4.5 Global Antiviral Drugs Market Value by Regions

5. Regional Market Analysis

  • 5.1 North America
    • 5.1.1 North America Antiviral Drugs Market by Value
    • 5.1.2 North America Antiviral Drugs Market Forecast by Value
    • 5.1.3 North America Antiviral Drugs Market by Region
    • 5.1.4 The U.S. Antiviral Drugs Market by Value
    • 5.1.5 The U.S. Antiviral Drugs Market Forecast by Value
    • 5.1.6 The U.S. Antiviral Drugs Market by Type
    • 5.1.7 The U.S. Branded Antiviral Drugs Market by Value
    • 5.1.8 The U.S. Branded Antiviral Drugs Market Forecast by Value
    • 5.1.9 The U.S. Generic Antiviral Drugs Market by Value
    • 5.1.10 The U.S. Generic Antiviral Drugs Market Forecast by Value
  • 5.2 Europe
    • 5.2.1 Europe Antiviral Drugs Market by Value
    • 5.2.2 Europe Antiviral Drugs Market Forecast by Value
  • 5.3 Asia Pacific
    • 5.3.1 Asia Pacific Antiviral Drugs Market by Value
    • 5.3.2 Asia Pacific Antiviral Drugs Market Forecast by Value
  • 5.4 Middle East & Africa
    • 5.4.1 Middle East & Africa Antiviral Drugs Market by Value
    • 5.4.2 Middle East & Africa Antiviral Drugs Market Forecast by Value
  • 5.5 Latin America
    • 5.5.1 Latin America Antiviral Drugs Market by Value
    • 5.5.2 Latin America Antiviral Drugs Market Forecast by Value

6. Market Dynamics

  • 6.1 Growth Drivers
    • 6.1.1 Increasing Prevalence of HIV Infections
    • 6.1.2 Upswing in International Tourism
    • 6.1.3 Growth in Geriatric Population
    • 6.1.4 Increasing Pharmaceutical R&D Spending
    • 6.1.5 Rapid Urbanization
    • 6.1.6 Upsurge in Healthcare Expenditures
    • 6.1.7 Growing Awareness About Various Viral infections and Diseases
  • 6.2 Key Trends and Developments
    • 6.2.1 Accelerating Growth Rates of Infectious Diseases
    • 6.2.2 Increasing Focus on Telehealth
    • 6.2.3 Growth in Pharmaceutical and Biotech Merger & Acquisition
    • 6.2.4 Emergence of Various Pandemic Diseases
  • 6.3 Challenges
    • 6.3.1 High Cost Involved in Drug Development
    • 6.3.2 Threats Associated with Drugs Counterfeiting
    • 6.3.3 Stringent Government Regulations

7. Competitive Landscape

  • 7.1 Global Market
    • 7.1.1 Key Players - Revenue Comparison
    • 7.1.2 Key Players - R&D Expenditure Comparison
    • 7.1.3 Key Players - Market Capitalization Comparison

8. Company Profiles

  • 8.1 Johnson & Johnson
    • 8.1.1 Business Overview
    • 8.1.2 Financial Overview
    • 8.1.3 Business Strategies
  • 8.2 Merck and Co.
    • 8.2.1 Business Overview
    • 8.2.2 Financial Overview
    • 8.2.3 Business Strategies
  • 8.3 AbbVie Inc.
    • 8.3.1 Business Overview
    • 8.3.2 Financial Overview
    • 8.3.3 Business Strategies
  • 8.4 Bristol-Myers Squibb
    • 8.4.1 Business Overview
    • 8.4.2 Financial Overview
    • 8.4.3 Business Strategies
  • 8.5 Gilead Sciences
    • 8.5.1 Business Overview
    • 8.5.2 Financial Overview
    • 8.5.3 Business Strategies
  • 8.6 Cipla
    • 8.6.1 Business Overview
    • 8.6.2 Financial Overview
    • 8.6.3 Business Strategies

List of Figures

  • Viral Life Cycle
  • Antiviral Agents For Different Indications
  • Development of Antiviral Drugs
  • Global Government Share on Health Spending (2019-2024)
  • Global Antiviral Drugs Market by Value (2015-2019)
  • Global Antiviral Drugs Market Forecast by Value (2020-2024)
  • Global Antiviral Drugs Market Value by Type (2019)
  • Global Branded Antiviral Drugs Market by Value (2015-2019)
  • Global Branded Antiviral Drugs Market Forecast by Value (2020-2024)
  • Global Generic Antiviral Drugs Market by Value (2015-2019)
  • Global Generic Antiviral Drugs Market Forecast by Value (2020-2024)
  • Global Antiviral Drugs Market Value by Application (2019)
  • Global Hepatitis Antiviral Drugs Market by Value (2015-2019)
  • Global Hepatitis Antiviral Drugs Market Forecast by Value (2020-2024)
  • Global HIV Antiviral Drugs Market by Value (2015-2019)
  • Global HIV Antiviral Drugs Market Forecast by Value (2020-2024)
  • Global Influenza Antiviral Drugs Market by Value (2015-2019)
  • Global Influenza Antiviral Drugs Market Forecast by Value (2020-2024)
  • Global Herpes Antiviral Drugs Market by Value (2015-2019)
  • Global Herpes Antiviral Drugs Market Forecast by Value (2020-2024)
  • Global Antiviral Drugs Market Value by Regions (2019)
  • North America Antiviral Drugs Market by Value (2015-2019)
  • North America Antiviral Drugs Market Forecast by Value (2020-2024)
  • North America Antiviral Drugs Market by Region (2019)
  • The U.S. Antiviral Drugs Market by Value (2015-2019)
  • The U.S. Antiviral Drugs Market Forecast by Value (2020-2024)
  • The U.S. Antiviral Drugs Market by Type (2019)
  • The U.S. Branded Antiviral Drugs Market by Value (2015-2019)
  • The U.S. Branded Antiviral Drugs Market Forecast by Value (2020-2024)
  • The U.S. Generic Antiviral Drugs Market by Value (2015-2019)
  • The U.S. Generic Antiviral Drugs Market Forecast by Value (2020-2024)
  • Europe Antiviral Drugs Market by Value (2015-2019)
  • Europe Antiviral Drugs Market Forecast by Value (2020-2024)
  • Asia Pacific Antiviral Drugs Market by Value (2015-2019)
  • Asia Pacific Antiviral Drugs Market Forecast by Value (2020-2024)
  • Middle East & Africa Antiviral Drugs Market by Value (2015-2019)
  • Middle East & Africa Antiviral Drugs Market Forecast by Value (2020-2024)
  • Latin America Antiviral Drugs Market by Value (2015-2019)
  • Latin America Antiviral Drugs Market Forecast by Value (2020-2024)
  • Global HIV Infected Population (2015-2019)
  • Global International Tourist Arrivals (2015-2019)
  • Global Geriatric Population - Age 65 and Above (2015-2019)
  • Global Pharmaceutical R&D Spending (2015-2019)
  • Global Urban Population (2015-2019)
  • Global Healthcare Expenditure Per Capita (2015-2019)
  • Global Growth Rate of Infectious Diseases Forecast (2017-2022)
  • Global Telehealth Patient Population (2015-2019)
  • Global Pharmaceutical and Biotech M&A (2015-2019)
  • Johnson & Johnson Total Sales and Net Earnings (2015-2019)
  • Johnson & Johnson Total Sales by Segments (2019)
  • Johnson & Johnson Total Sales by Regions (2019)
  • Merck and Co. Sales and Net Income (2015-2019)
  • Merck and Co. Sales by Segments (2019)
  • Merck and Co. Sales by Regions (2019)
  • AbbVie Inc. Net Revenue and Net Earnings (2015-2019)
  • AbbVie Inc. Net Revenue by Product (2019)
  • AbbVie Inc. Net Revenue by Regions (2019)
  • Bristol-Myers Squibb Total Revenue and Net Earnings (2015-2019)
  • Bristol-Myers Squibb Total Revenue by Operations (2019)
  • Bristol-Myers Squibb Total Revenue by Regions (2019)
  • Gilead Sciences Total Revenue and Net Income (2015-2019)
  • Gilead Sciences Total Revenue by Operations (2019)
  • Gilead Sciences Total Revenue by Regions (2019)
  • Cipla Revenue and Profit (2015-2019)
  • Cipla Revenue by Segments (2019)
  • Cipla Revenue by Regions (2019)

List of Tables

  • Some Major Antiviral Compounds Developed and Approved for Use in Humans
  • Global COVID-19 Confirmed Deaths
  • COVID-19 Antiviral Candidate Drugs in Phase III-IV Trials
  • Major Clinical Studies of Remdesivir
  • Key Players - Revenue Comparison (2019)
  • Key Players - R&D Expenditure Comparison (2019)
  • Key Players - Market Capitalization Comparison (2020)
Back to Top